Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC):... by Auliac, J. B., Fournier, C., Audigier Valette, C., Perol, M., Bizieux, A., Vinas, F., Decroisette Phan van Ho, C., Bota Ouchlif, S., Corre, R., Le Garff, G., Fournel, P., Baize, N., Lamy, R., Vergnenegre, A., Arpin, D., Marin, B., Chouaid, C., Gervais, R.

Get full text